Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 80Terminated 29Unknown 11Withdrawn 3Active not recruiting 3Recruiting 2Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 9Vincristine 6Specimen Handling 6Prednisone 6Rituximab 5Doxorubicin 5Magnetic Resonance Spectroscopy 4zanubrutinib 3prednylidene 3fludarabine 3deltacortene 3Biopsy 3tazemetostat 2fludarabine phosphate 2Radiotherapy, Intensity-Modulated 2Melphalan 2Etoposide 2Drug Therapy 2CT-P10 2Azacitidine 2Antibodies, Monoclonal 2vactosertib 1tisagenlecleucel 1sargramostim 1pembrolizumab 1obinutuzumab 1mogamulizumab 1glucarpidase 1duvelisib 1brincidofovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Alemtuzumab × Lymphoid × Clear all
NCT01982175 2022-06-21

CLL004

Shanghai Zhangjiang Biotechnology Limited Company

Phase 2 Suspended
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡